Retatrutide appears to be a new medication in the fight against obesity. This novel drug, categorized as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in research studies. By stimulating these receptors, Retatrutide suppresses appetite, {promotesinsulin secretion, and ultimately results in significant reduction in body mass.